Plurima S.p.A.

11/22/2021 | News release | Distributed by Public on 11/22/2021 03:08

How does real-world handling affect protein drugs? IMI invests in a new international research project


Plurima was established in Umbria, Italy, thanks to the brilliant intuition of its founder, Professor Tito Marconi, who was the first to propose the outsourced management of document archives of both public and private companies at a national level.

Since then, Plurima has experienced a continuous and constant growth, all while consolidating the dual strategy of strengthening its presence on the territory and offering complete and innovative services.

In fact, the increase in interest by Client companies has matched the expansion of Plurima's intervention sectors, such as integrated logistics services, pharmaceutical warehouse management and healthcare transport.

"Excellence" is the watchword for Plurima, which for over thirty years has shown total dedication to service, determination in the pursuit of the best performance and the ability to interpret - if not even anticipate - market demands.

The numbers speak for themselves: currently, Plurima Group is a company with over 45 million euro in turnover, more than 35 branch offices and a staff of over 800 people.

The achievement of these incredible results was been possible thanks to the perfect balance between the continuous search for innovation and the respect for traditional values, that makes Plurima one of the largest Italian companies in the health logistics and drug storage sector.

About the Innovative Medicines Initiative

The Innovative Medicines Initiative (IMI) is a joint undertaking between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need.


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101007939. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA companies.